Genentech Oncology
aDeveloped in collaboration with Array Biopharma.bDeveloped in collaboration with Exelixis. cJoint project with AbbVie. dManaged by Repare Therapeutics. eDeveloped in collaboration with Immunocore. fDeveloped in collaboration with Relay Therapeutics. gDeveloped in collaboration with Chugai. hDeveloped in collaboration with Xencor.
Current as of October 18, 2022. The trial information is taken from ClinicalTrials.gov.
Roche. 2022 Q3 results. October 18, 2022. Accessed October 25, 2022. https://www.roche.com/investors/events/q3-2022
Roche. 2022 Q3 results. October 18, 2022. Accessed October 25, 2022. https://www.roche.com/investors/events/q3-2022
The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. Do you wish to proceed?
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.